SNTIHealthcare · BiotechnologySNTI Stock Forecast: Senti Biosciences Holdings, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Senti Biosciences Holdings, Inc. hold a median 12-month price target of $14 — +5194.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 12 Oct 2026 — in the upper half.
SNTI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Senti Biosciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Volatility (10): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
SNTI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNTI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5194.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | Chardan Capital | Maintains | Buy | $11 → $12 |
| 30 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 9 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Nov 2025 | Leerink Partners | Initiates | Outperform | — |
| 14 Oct 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 12 June 2025 | Chardan Capital | Maintains | Buy | — |
| 6 June 2025 | Laidlaw & Co. | Initiates | Buy | — |
| 2 May 2025 | Chardan Capital | Maintains | Buy | — |
| 4 Dec 2024 | Chardan Capital | Maintains | Buy | — |
| 2 Dec 2024 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2023 | Chardan Capital | Reiterates | Buy | — |
| 11 May 2023 | Chardan Capital | Maintains | Buy | — |
| 24 Mar 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 23 Mar 2023 | Chardan Capital | Maintains | Buy | — |
| 30 Jan 2023 | Chardan Capital | Maintains | Buy | — |
| 27 Jan 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 16 Dec 2022 | JP Morgan | Initiates | Neutral | — |
| 7 Oct 2022 | Morgan Stanley | Initiates | Equal-Weight | — |
| 29 Sept 2022 | B of A Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNTI appears on the weeks it earns a place.
SNTI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Senti Biosciences Holdings, Inc. returned −84.8% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SNTI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Senti Biosciences Holdings, Inc. (SNTI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 4.3×
- Price / sales
- 180.4×
- Price / book
- −2.9×
- EV / EBITDA
- −0.5×
Cheaper than 67% of US stocks
Cheaper than 3% of US stocks
Cheaper than 96% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- 6.3%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −79370.6%
- Net margin
- 0.0%
Higher than 42% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −466.5%
- Return on assets
- −65.6%
- Dividend yield
- 0.0%
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Senti Biosciences Holdings, Inc. (SNTI) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Senti Biosciences Holdings, Inc. has a market value of $9.9M and an enterprise value of $23.5M.
Revenue in the twelve months to 30 June 2026: $55K. The latest quarter grew 6.3% year on year.
Net income over the same four quarters: −$49.6M, a −90116.4% net margin.
Diluted earnings per share, trailing twelve months: $−1.77.
Free cash flow in the twelve months to 30 June 2026: −$38.1M.
Trailing P/E: 4.3×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Senti Biosciences Holdings, Inc. employs 39 people — $1K of revenue per employee.
Data provided by Twelve Data
SNTI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Senti Biosciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about SNTI stock
What is the SNTI stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Senti Biosciences Holdings, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SNTI stock a buy right now?
Of the 2 analysts covering Senti Biosciences Holdings, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Senti Biosciences Holdings, Inc. 61 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SNTI?
As at 12 Oct 2026, Senti Biosciences Holdings, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
Will SNTI stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +5194.1% from the last close, and Ticker Nerd's factor model ranks Senti Biosciences Holdings, Inc. 61 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SNTI stock forecast for 2030?
No analyst covering Senti Biosciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.
How has SNTI stock performed over the past year?
Senti Biosciences Holdings, Inc. returned -84.8% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Senti Biosciences Holdings, Inc. do?
Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies built with its proprietary Gene Circuit platform.
About Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies built with its proprietary Gene Circuit platform. The company designs engineered medicines that can sense biological signals, make programmed decisions, and respond with greater precision in complex disease environments. Its current work centers on advanced cell therapies for difficult-to-treat cancers and other incurable diseases, with applications across both liquid and solid tumors. Senti Biosciences Holdings, Inc. develops these programs using synthetic biology tools intended to improve targeting, control, and selectivity in therapeutic cells. Headquartered in South San Francisco, California, the company operates in the biotechnology and cell therapy markets, where it contributes to the broader effort to create more precise and controllable genetic medicines.
CEO Dr. Timothy K. Lu M.D., Ph.D. · 39 employees · United States · https://www.sentibio.com